Jonathan Schwartz
Chief Tech/Sci/R&D Officer en ROCKET PHARMACEUTICALS, INC. .
Fortuna: 5 M $ al 31/03/2024
Perfil
Jonathan David Schwartz is currently the Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, Inc. He previously worked as the Vice President-Clinical Science at Eli Lilly & Co. and as the Vice President-Clinical Development at Stemline Therapeutics, Inc. from 2014 to 2016.
He also held the position of Associate Professor at The Mount Sinai Medical Center, Inc. and Chief Medical Officer & Head-Clinical Development at Rocket Pharmaceuticals Ltd.
Dr. Schwartz obtained a doctorate degree from Washington University in St. Louis and an undergraduate degree from Brown University.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
25/03/2024 | 172 413 ( 0.19% ) | 5 M $ | 31/03/2024 |
Cargos activos de Jonathan Schwartz
Empresas | Cargo | Inicio |
---|---|---|
ROCKET PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 26/03/2024 |
Antiguos cargos conocidos de Jonathan Schwartz.
Empresas | Cargo | Fin |
---|---|---|
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2016 |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | - |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
The Mount Sinai Medical Center, Inc.
The Mount Sinai Medical Center, Inc. Hospital/Nursing ManagementHealth Services The Mount Sinai Medical Center, Inc. operates charitable teaching hospitals. The non-profit company is based in New York, NY. The CEO of the company is Gino Santorio. | Corporate Officer/Principal | - |
Formación de Jonathan Schwartz.
Washington University in St. Louis | Doctorate Degree |
Brown University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
ROCKET PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
The Mount Sinai Medical Center, Inc.
The Mount Sinai Medical Center, Inc. Hospital/Nursing ManagementHealth Services The Mount Sinai Medical Center, Inc. operates charitable teaching hospitals. The non-profit company is based in New York, NY. The CEO of the company is Gino Santorio. | Health Services |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Jonathan Schwartz